HIV /AIDS : NEW RESEARCH OF MEDICINES AND VACCINES TO CONTROL IT

HIV /AIDS : NEW RESEARCH OF MEDICINES AND VACCINES TO CONTROL IT

PROF.DRRAM ,HIV/AIDS,SEX DISEASES,SEX WEAKNESS & ABORTION SPECIALIST
profdrram@gmail.com,+917838059592,+919832025033 DELHI –NCR,INDIA
FOLLOW ON FACE BOOK:www.facebook.com/drramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram

Researchers are looking for new types of medications that will eliminate or partially eliminate the need for ongoing ARV treatment. However, research is being hindered and not by a lack of knowledge or ideas on how to slow the virus but by financial considerations. One such drug whose progress is being slowed is a therapeutic vaccine called GenePro (delta4SHIVku2).
As our understanding of the pathogenesis of HIV and the effects the virus has on the immune system has progressed through the years, so has and is the premise for the role of therapeutic vaccines.A successful therapeutic vaccine is now thought to be one that produces a CD8+ memory cell response capable of killing infected cells and decreasing viral load to undetectable levels. Recent data aimed at eliciting a cure for HIV supports this hypothesis and the importance of CD8 cells, suggesting that a strong CD8 response is necessary in combination with awakening latent HIV in order to eliminate HIV reservoirs, highlighting the importance therapeutic vaccines may hold in maintaining viral clearance.

CD8 responses are believed to be lost in most HIV patients with the possible exception of elite responders. Elite responders (approximately 5% of people living with HIV) are able to maintain a suppressed viral load without the use of HIV antiretrovirals. Elite responders are able to maintain an undetectable viral load (below 50 copies/ml), sustain a CD4 count above 500 and do not experience symptoms related to HIV, for a period greater than 10 years, all in the absence of ARVs.Research indicates that many elite controllers not only continue to possess CD8 cells after infection but that these cells have a superior capacity to proliferate. Although additional host restriction mechanisms appear to be necessary to elicit the viral control elite controllers possess, data indicates a strong CD8 response has been shown to be present in the majority of elite controllers and in many cases are a major factor in controlling viremia.

GenePro, made by a company named ImmunoGenetix, is a DNA based therapeutic vaccine, with a consistent lentiviral composition. This differentiates GenePro as it more closely mimics the virus, for appropriate immune responses. In mouse model and primates GenePro produced potent CD8 cells similar to those seen in elite controllers. These CD8 cells maintained HIV specific memory through out the life of the animals.

GenePro contains seven proteins which in vitro and animal studies show an ability to produce high levels of non-infectious proteins which elicits a much stronger immune response then other DNA vaccines that have been studied. GenePro stimulates a potent antibody response without the need for protein or viral vector boosts. GenePro doesn’t integrate into the genome host so there is no chance of mutations and it does not carry infectious virus. Electroporation is used to introduce it into the body, affording for superior infiltration into cells.

In this case, the makers of GenePro were awarded $21 million dollars in NIH grants to develope and take the therapeutic vaccine to its present point. In the case of HIV, simple common sense dictates that funding a drug such as a therapeutic vaccine that shows potential in allowing for less use of ARV’s is not only an ethical and beneficial pursuit but is a common sense approach to tackling the growing cost of life long ARVs with a cost effective solution and is well worth the investment.

Like ·  · Share · Stop Notifications · Promote